TP53 and head and neck squamous cell carcinoma: It has been recently suggested that TP53 missense mutations occurring in evolutionary conserved residues are likely to confer a gain-of-function, ultimately predicting poor treatment response and a shorter survival in HNSCC patients [14, 15].